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Abstract Benign hereditary chorea (BHC) is a rare autosomal
dominant condition characterized by early onset, non-
progressive chorea, usually caused by mutations in the thyroid
transcription factor-1 gene (TITF1). We describe a novel muta-
tion arising de novo in a proband presenting in infancy with
delayed walking and ataxia. She later developed chorea, then
hypothyroidism and a large cystic pituitary mass. Her daughter
presented in infancy with delayed walking and ataxia and went
on to develop non-progressive chorea and a hormonally inactive
cystic pituitary mass. Mutational analysis of the whole coding
region of the TITF1 gene was undertaken and compared with a
population study of 160 control subjects. This showed that both
affected subjects have a heterozygous A > T substitution at
nucleotide 727 of the TITF1 gene changing lysine to a stop
codon at residue 211. Genetic analysis of parents and siblings
of the proband confirmed that the mutation arose de novo in the
proband. The mutated lysine is an evolutionarily highly con-
served amino acid in the protein homoeodomain (HD) where
most point mutations associated with BHC are located. The
range of mutations in BHC is reviewed with particular emphasis
on pituitary abnormalities. Cystic pituitary masses and
abnormalities of the sella turcica are reported in just 6.4 % of
published cases. This is a new nonsensemutation associatedwith
ataxia, benign chorea and pituitary abnormalities which further
extends the phenotype of this condition. Mutational screening of
TITF1 is important in cases of sporadic or dominant juvenile-
onset ataxia, with mild chorea where no other cause is found,
particularly if pituitary abnormalities are seen on imaging.
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Abbreviations
BHC Benign hereditary chorea
C-AD C-terminal activation domain
CT Computerized tomography
HD Homeodomain
MR Magnetic resonance
N-AD N-terminal activation domain
NKX2-1 NK2 homeobox 1 gene
NLS Nuclear localization signal
PCR Polymerase chain reaction
RET Receptor tyrosine kinase gene
SARA Scale for the assessment and rating of ataxia
SSCP Single-strand conformation polymorphism
T/EBP Thyroid-specific enhancer-binding protein
TITF1 Thyroid transcription factor-1 gene
TTF-1 Thyroid-specific transcription factor-1
Background
Benign hereditary chorea (BHC) (OMIM 118700) is a rare
autosomal dominant movement disorder characterized by a
non-progressive form of chorea with a prevalence of around
two in 10,000,000 [1] and penetrance estimated to be 100 % in
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men and 75% inwomen [2]. Affected individuals may also have
pulmonary disease and/or congenital hypothyroidism [3]. For
this reason, BHC is described as part of the ‘brain-lung-thyroid
syndrome’. Age at onset is usually before the age of 5 years,
although this can vary from early infancy to late childhood and
adolescence [4, 5]. Delayed motor milestones, specifically late
walking, clumsiness and frequent falls, characterize affected
children [6]. Speech and intellect are normally unaffected or
minimally affected, distinguishing BHC from Huntington’s dis-
ease. Progression during adulthood is rare, and theremay even be
improvement in symptoms. Life expectancy is normal [7]. A
general therapeutic treatment is not available, although levodopa
administration is sometimes effective particularly for gait diffi-
culties [8]. Other successful treatments have included methyl-
phenidate and corticosteroids [9, 10].
The condition shows considerable intra- and inter-familial
phenotypic variability. Additional atypical features include
dysarthria and gait disturbances [11], mental impairment
[12] or axial dystonia and progression in adulthood [13].
Due to the overlapping symptoms and age at onset, differen-
tial diagnosis between BHC and myoclonus-dystonia syn-
drome is particularly difficult [1, 14, 15]. Both conditions
share similar age at onset, dominant inheritance with variable
penetrance, minimal progression and the possibility of addi-
tional dystonia with no other neurological abnormalities [16].
Breedveld and colleagues [5] first identified a de novo dele-
tion on chromosome 14q13, spanning the TITF1 gene, which
segregated with the disease in a small BHC family. Seventy-
seven mutations of the TITF1 gene have subsequently been
identified in BHC patients, including large and small deletions,
missense and nonsense mutations. TITF1 alias NKX2-1 encodes
thyroid-specific transcription factor-1 (TTF-1), a thyroid-specific
enhancer-binding protein (T/EBP). The protein was originally
identified because it binds to the thyroglobulin promoter and
regulates the expression of thyroid-specific genes involved in the
production of thyroglobulin, thyroid peroxidase and the thyro-
tropin receptor. It has also been shown to regulate the expression
of genes involved in the secretion of surfactant proteins andClara
cell secretory protein in the lungs [17] and in organogenesis in
the thyroid, lung and brain, particularly the ventral forebrain,
posterior pituitary and hypothalamus [18–21]. TITF1 accounts
for about 50% of the mutations associated with BHC suggesting
a genetic heterogeneity for this disease [5]. A second BHC locus
has been identified in two Japanese families with adult-onset
disease which maps to chromosome 8q22.2-q22.3 [22].
Methods
Patients
This research was approved by the London (Queen Square)
NHS Research Ethics Committee (reference 04/N034) at the
National Hospital for Neurology and Neurosurgery, London,
UK. The patients were identified through the Ataxia Centre of
the National Hospital for Neurology and Neurosurgery. Af-
fected family members provided fully informed signed con-
sent. Patients underwent clinical neurological examination
including the scale for the assessment and rating of ataxia
(SARA) as well as MR imaging.
Mutational Analysis
Genomic DNA was amplified by PCR using primer pairs as
described by Breedveld and colleagues [5]. The DNA frag-
ments obtained were sequenced by Eurofins MWG Operon
Sequencing Service. Paternity was confirmed by using DNA
polymorphisms.
Population Study
A sample of 160 control subjects was screened for the muta-
tion found in our patient through single-strand conformation
polymorphism (SSCP) analysis. A 516-bps DNA fragment
was amplified by polymerase chain reaction (PCR) with the
following primer pair: TITF-3AFN/TITF-3AR [23]. The PCR
product was digested with restriction endonuclease BanI. The
three fragments obtained (87, 139 and 290 bps) were analysed
by SSCP on a GenePhor Electrophoresis Unit (Pharmacia
Biotech), using non-denaturing precast acrylamide gels
(GeneGelExcel 12.5, Pharmacia Biotech).
Results
Proband History
The proband is a 49-year old lady born via spontaneous
vaginal delivery after a normal pregnancy. Her mother de-
scribed her as a ‘floppy’ baby. She began to walk late and with
difficulty, holding on to furniture while walking. There were
no abnormalities in speech development, but she was diag-
nosed with cerebellar ataxia at age 2 years. She received
intensive physiotherapy and attended a school for disabled
children until 16 years old and then completed further educa-
tion. She has been working and living independently since
18 years of age.
She experienced lifelong balance problems. At around
16 years of age, the balance worsened because of sudden jerky
or choreic movements and was started on benztropine at age
17. This improved her symptoms, but she stopped taking this
drug at the beginning of her first pregnancy and did not restart
it. There have never been any problems relating to
swallowing, double vision, bowel or bladder function. She
remained well until 40 years of age when she was investigated
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for weight gain. Hypothyroidism was diagnosed and treated
successfully with levothryoxine. The remainder of the pitui-
tary hormonal profile was normal. Respiratory function tests
were also normal. Other than this, she was stable between 17
and 40 years of age. Since age 40, she has experienced more
jerky involuntary movements and also falls.
On examination, her gait was mildly ataxic, but she was
able to walk in tandem and hop on one foot. She had clear
choreic jerks and dystonic movements of her head and shoul-
ders and dystonic posturing of the hands while walking.
Romberg’s test was negative. Extraocular movements were
full, but she had ocular apraxia with difficulty initiating sac-
cades, broken pursuit movements, hypometric saccades and
gaze impersistence. The cranial nerve examination was other-
wise normal. Mild dysarthria was present. Upper and lower
limb tone and power were normal, but there was some
dysdiadochokinesia due to intrusion of involuntary move-
ments. There were choreic movements in both feet. The
tendon reflexes were present and symmetrical, with flexor
plantar reactions and normal sensation throughout. The scale
for the assessment and rating of ataxia (SARA) showed gait 2,
stance 1, sitting 1, speech 1, finger chase 1–1, nose-finger test
1–1, fast alternating hand movements 1–0, heel-shin slide
1–1.
MR imaging at age 45 showed a cystic structure within an
expanded pituitary fossa, abutting but not compromising the
anterior visual pathways (see Fig. 1). This was felt to represent
an old macroadenoma which had undergone degeneration.
The remainder of the brain and brainstem, including the
posterior fossa structures, was normal. Subsequent computer-
ized tomography (CT) scan showed a well-defined, rounded,
homogeneous lesion of fluid attenuation with erosion and
thinning of the sellar walls but without internal calcification,
in keeping with a slowly growing cystic lesion.
Family History
The proband’s daughter is aged 26 and was born via a normal
pregnancy and spontaneous vaginal delivery. When she was
3–4 months old, her grandmother noticed she was floppy. She
started crawling at 8 months, had problems standing up until
well over a year old and did not walk independently until she
was 2 years old, due to ataxia. She received intensive physio-
therapy that helped her walk more steadily but always had
problems maintaining balance on standing. She has had re-
current abnormal jerky movements of all four limbs since
childhood, after improvement of her ataxia, which subse-
quently improved in adulthood. There are no speech prob-
lems, but swallowing can be ‘slow’, as she described. She has
had recurrent chest infections over many years. There is no
formal respiratory diagnosis.
On examination, she had normal gait and tandem walk and
was able to hop on one foot. Romberg’s test was negative
although there were some choreic movements of the head and
legs on standing. There were choreic movements in the upper
limbs but no impersistence of the tongue or ‘milking sign’
(alternating contraction and relaxation of the hand). There was
no dysarthria. Extraocular movements and speech were unre-
markable. Tone, power and coordination were normal. Deep
tendon reflexes were present and symmetrical with flexor
plantar reflexes and normal sensation. SARA score was 0/40.
MR imaging showed a mildly expanded pituitary fossa
with a cyst lying in the posterior aspect of the fossa displacing
the infundibulum and adenohypophysis anteriorly (see Fig. 1).
The intracranial appearances were otherwise normal with no
cerebellar, cerebral or basal ganglia volume loss or abnormal
signal change. The only abnormalities on the biochemical
pituitary profile were slightly low prolactin level and slightly
raised thyroid-stimulating hormone (with normal free T4
level).
There is no family history of similar disorders (see Fig. 2).
One of the proband’s brothers has clinically confirmed relaps-
ing remitting multiple sclerosis which responds to steroids. He
had normal development and no choreic movements. There
are four other siblings and seven nieces and nephews, all of
whom are unaffected. A paternal aunt had Alzheimer’s dis-
ease. The proband’s father had colon cancer. Her mother and
siblings were otherwise unaffected. The proband’s mother and
one sister were both examined and found to be neurologically
normal.
Genetic Analysis
Sequencing of exons 1, 2 and 3 of the TITF1 gene of the
proband’s DNA revealed a heterozygous A > T variation at
nucleotide 727 [GenBank: NM_001079668.2], resulting in a
substitution of a lysine residue at codon 211 for a stop codon
[K211X, GenePept: NP_001073136.1]. The mutated lysine is
an evolutionarily highly conserved amino acid in the protein
HD where most of the point mutations associated with BHC
are located. The same mutation was identified in her daughter,
but not found in her parents, brothers and sisters. The popu-
lation study excluded the presence of this variation in 160
control European subjects (320 chromosomes).
Discussion
We describe a novel mutation p.K211X in exon 3 of the TITF1
gene encoding TTF-1 found in one patient and her child. The
mutated protein is predicted to be truncated in the protein HD,
located between the amino acids 190 and 249 [24], where the
majority of the missense and nonsense mutations associated to
BHC are located. This variation is the first de novo nonsense
mutation described in TITF1, the others being large or small
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deletions, insertions and missense or splice-site mutations.
This mutation segregates in a family with an early onset ataxia
followed later with choreic movements.
To date, 78 mutations associated with BHC have been
reported in the TITF1 gene including the present paper (see
Table 1). Thirty-four are de novo (43.6%), 29 (37.2%) showed
an autosomal dominant transmission and, for 15, the transmis-
sion was not defined (19.2 %). In one case, the same mutation
V235P reported by Krude and colleagues [25] and Uematsu
and colleagues [26] is described as a de novo mutation in the
first paper and with autosomal dominant transmission in the
second. The two patients likely belong to different populations,
the first of German origin and the second of Japanese origin.
The reason for such a high rate of de novo mutations in this
gene is not clear. A reduction of fecundity or fitness conferred
by some TITF1 mutations could be possible. The wide spec-
trum of symptoms related to TITF1mutations may support this
hypothesis, including severe respiratory distress leading to an
early death [27] and atypical features such as developmental
delay [28] and microcephaly [29].
The high rate of de novo mutations and incomplete pene-
trance has significant implications for clinical diagnosis and
genetic counselling. Since evidence of autosomal dominant
inheritance is absent in many cases of BHC, mutational
screening of TITF1 is important not only in cases of
juvenile-onset chorea but also in early onset ataxia where no
other cause is found, as was the case with our case when she
first presented. Importantly, the risk of transmission to
Fig. 1 MR imaging. Imaging of proband showing cystic pituitary mass (open arrow) a T2-weighted axial MRI, b axial CT, c sagittal CT; imaging of
proband’s daughter showing cystic pituitary mass (solid arrow) d T2-weighted coronal MRI, e T2-weighted axial MRI
Fig. 2 Family tree. Affected
individuals II 05 and III 01 carry
the K211X mutation. II 03 has
clinically confirmed relapsing
remitting multiple sclerosis. For I
01, paternity was confirmed via
DNA polymorphisms
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Table 1 Mutations in TITF1 with neurological, thyroid, lung or pituitary involvement
Mutation Exon Mutation Transmission Pituitary Brain Thyroid Lung Origin Reference
Stop 2 p.Y98X AD – + + + Japan [39]
Stop 2 p.Q107X AD – + – – Spain [40]
I 2 p.Y116fsX323 De novo – + + + NR [41]
I 2 p.Y116X AD NR + – – NR [42]
Stop 2 p.C117X ? NR + + + NR [25]
D 2 p.P129fsX307 De novo NR + – + US [43]
Stop 2 p.Y144X ? NR + + – France [44]
Stop 2 p.Y144X ? NR + + + US [43]
SP 2-3 c.463 + 1_463 + 4del AD NR + + – NR [42]
SP 2-3 c.463 + 1G > A De novo – + + + Spain [45]
SP 2-3 c.464-9C > A AD – + + – Japan [46]
SP 2-3 c.464-1G > A De novo – + + + Spain [47]
SP 2-3 c.464-2A > C AD – + – – UK [1]
SP 2-3 c.464-2A > T AD – + – NR Canada [31]
SP 2-3 c.464-2A > G AD – + + + US [48]
SP 2-3 c.464-2A > G De novo – + + + France [49]
D 3 p.S163fsX2 De novo NR + + + NR [42]
Stop 3 p.S175X AD Empty sella + + + Italy [28, 34]
D 3 p.P185fsX250 De novo NR + + + US [43]
I/D 3 p.P187fsX196 De novo – + + + Japan [50]
D 3 p.R195fsX32 AD NR + + + Brazil [51]
MS 3 p.R195W De novo NR + + + US [43]
MS 3 p.L197P ? NR + – + US [43]
MS 3 p.F198L AD NR – – + US [43]
MS 3 p.F198L ? NR – – + US [43]
MS 3 p.F198L ? NR – – + US [43]
Stop 3 p.S199X ? NR + + – NR [25]
Stop 3 p.E205X AD – + – – Germany [8]
MS 3 p.L206V De novo – + – – France [42, 49]
Stop 3 p.R208X AD – + – – UK [23]
Stop 3 p.K211X De novo Cystic mass + + – UK Present study
MS 3 p.Y215D De novo NR + + – NR [42]
Stop 3 p.S217X AD – + + – Ashkenazi Jewish [52]
MS 3 p.L224R AD NR + + – NR [42]
I 3 p.A225fsX228 De novo NR + – – NR [25]
MS 3 p.P233L De novo NR + + – France [49]
MS 3 p.V235P De novo Cystic mass + + + NR [25]
MS 3 p.V235P AD – + + – Japan [26]
MS 3 p.I237F De novo NR NR + + French Canadian [27]
MS 3 p.I237M De novo NR – + + US [53]
MS 3 p.W238L AD – + NR NR US [5]
MS 3 p.Q240P De novo – + + – France [42, 49]
MS 3 p.R243S AD – + NR NR Netherlands [5]
MS 3 p.R243P AD NR + – – NR [42]
Stop 3 p.Y244X AD NR + + – NR [42]
Stop 3 p.Q249X AD – + – – Portugal [54]
D 3 p.G266del AD – + NR + Italy [55]
I 3 p.G269_271dupGGGa ? NR + – + US [43]
I/D 3 p.274_280del7aa and p.G273fsX152 ? NR + + + US [43]
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subsequent generations remains 50 % even in such seemingly
sporadic cases. Mutational screening should also be consid-
ered in cases of autosomal dominant early onset ataxia with
extracerebellar signs—the so-called ADCA type I according
to the Harding classification—if other more common causes
have been excluded and particularly if chorea is present [30].
The cause of the proband’s ataxia is not clear as there was
no evidence of cerebellar or frontal atrophy on imaging and no
clinical evidence of sensory neuropathy. Histopathological
studies in BHC are few and associated with sparse changes.
Kleiner-Fisman et al. [31] found no gross or microscopic
abnormalities apart from some mild frontal-parietal-temporal
atrophy and non-specific astrocytosis of the globus pallidus,
thalamus, hippocampus and periaqueductal grey matter. Sub-
sequent re-examination of the same brain showed a reduced
density of striatal met-enkephalin- and substance-P-
immunoreactive nerve fibres [32]. Of note, this patient
did not show cerebellar ataxia. Therefore, in our case,
we hypothesize that there may be a dysfunction of the
basal ganglia-cerebellar loops [33] responsible for the
cerebellar syndrome.
The distribution of point mutations in the TITF1 gene
causing BHC is uneven. No mutations are described in exon
1, whereas the acceptor splice site at exon 3 appears to be a
mutational hot-spot with six mutations affecting this site re-
ported. Mutations truncating the protein span the whole gene
affecting all protein domains. Missense mutations associated
with BHC are exclusively located in the HD and not in other
protein regulatory domains, presumably impairing the binding
activity of the transcription factor with DNA.
Cystic pituitary masses and abnormalities of the sella
turcica are reported in just a few cases: five out of the 78
Table 1 (continued)
Mutation Exon Mutation Transmission Pituitary Brain Thyroid Lung Origin Reference
D p.A280fsX161 AD NR + + + France [44]
D 3 p.L293del De novo NR + + + NR [42]
D 3 p.G303fsX77 AD – + NR NR UK [5]
D 3 p.A306fsX350 AD – + + – Spain [56]
D 3 p.Q327fsX121 De novo – + + + Netherlands [3]
I 3 p.H349fsX90 De novo NR + + + US [43]
D 3 p.Q357fsX24 AD – + – – NR [57]
D 3 p.S366fsX67 ? NR – + + US [43]
I 3 p.T389fsX52 ? NR + + + US [43]
LD del 14q13-q21 De novo – NR + + Belgium [58]
LD del 14q12-q13.3 De novo –b + + + NR [29]
LD del 14 1.2 MB De novo – + NR NR Italy [5]
LD del 14 1.2 MB AD Stalk duplication + + NR Italy [35]
LD del 14q11.2-q13.3 ? Cystic mass + + + NR [25]
LD del 14q13 De novo – + + + France [49]
LD del 14 0.9 MB AD – + + + France [59]
LD del 14q12-q13 De novo – + + + Japan [26]
LD del 14q13.2-q22.1 De novo NR + – – NR [42]
LD del 14q13.2-q21.2 De novo NR + + – NR [42]
LD del 14q13.3 De novo NR + + – NR [42]
LD del 14q13.1-q21.1 De novo NR + + + US [43]
LD del 14q13.3 ? NR + + + US [43]
LD del 14q13.3-q21.1 De novo NR + + + US [43]
LD del 14q13.1-q21.1 De novo NR + + + US [43]
LD DEL ex1-2 ? NR + + + US [43]
LD del 14q13.2-q21.1 De novo – + + – Australia [60]
LD del 14q13.3 AD NR + + + France [44]
LD del 14q13.3 De novo NR + + – France [44]
SP splicing mutation, I/D small insertion/deletion, LD large deletion, M missense, AD autosomal dominant, NR not recorded, ? unknown
a Two unrelated patients
b No pituitary abnormality but cystic mass of cavum septum pellucidum
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cases hitherto published (6.4 %) (see Table 1) associated with
missense and nonsense mutations and large deletions [25, 28,
34, 35]. Silberschmidt and colleagues [36] defined in vivo the
role of two different TITF1 transcriptional activation domains
flanking the nuclear localization signal (NLS) and the HD,
namely the N-terminal (N-AD) and the C-terminal (C-AD)
activation domains. These portions of the protein have differ-
ent developmental functions. In particular, the N-AD seems to
be essential for pituitary morphogenesis whereas both are
essential for thyroid morphogenesis. None of the reported
mutations associated with pituitary defects is located in the
N-AD. However, this is not necessarily surprising, since trun-
cated proteins are unable to translocate into the nucleus,
notwithstanding the presence of the NLS in many cases
[28], probably impairing the function of N-AD. Furthermore,
the remarkable phenotypic heterogeneity observed in BHC
families showing pituitary abnormalities suggests that other
factors may modify TITF1 activity in pituitary development.
These may include other genes, transcription factor
haploinsufficiency of various causes [37] and epigenetic
mechanisms [38]. Much further work remains to elucidate this
problem.
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